Both the companies intend to lay emphasis on discovering small molecule drugs against oncology-relevant protein-protein interactions.
As per the deal, Forma will receive a total of $65m in up-front payments and research funding to screen for and optimize compounds against multiple oncology targets over the upcoming four years.
Furthermore, Forma may be entitled to receive up to $750m in pre-commercial milestones for programs resulting from the collaboration.
Forma Research and Development head and senior vice president Kenneth Bair said many un-druggable and/or novel targets in oncology involve protein-protein interactions.
"We are really excited about tackling these essential targets with Boehringer Ingelheim," Bair added.